Hamelin Paul 4/A
4/A · SAVIENT PHARMACEUTICALS INC · Filed Jun 26, 2008
Insider Transaction Report
Form 4/AAmended
Hamelin Paul
President
Transactions
- Exercise/Conversion
Common Stock, $.01 par value per share
2008-06-23$5.11/sh+5,000$25,550→ 43,419 total - Sale
Common Stock, $.01 par value per share
2008-06-19$24.89/sh−1,928$47,994→ 38,419 total - Sale
Common Stock, $.01 par value per share
2008-06-23$25.75/sh−5,000$128,751→ 38,419 total - Exercise/Conversion
Common Stock, $.01 par value per share
2008-06-19$12.11/sh+1,928$23,348→ 40,347 total - Exercise/Conversion
Option to Purchase Common Stock, $.01 par value
2008-06-23$5.11/sh−5,000$25,550→ 40,000 totalExercise: $5.11From: 2007-05-23Exp: 2016-05-23→ Common Stock, $.01 par value per share (5,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock, $0.01 par value
2008-06-19$12.11/sh−1,928$23,348→ 43,197 totalExercise: $12.11From: 2007-12-08Exp: 2016-12-08→ Common Stock, $.01 par value per share (1,928 underlying)
Footnotes (4)
- [F1]This sale was made pursuant to a trading plan adopted on June 14, 2007 by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
- [F2]Represents the average sale price. The highest price at which shares were sold was $24.94 and the lowest price at which shares were sold was $24.84.
- [F3]Due to an administrative error, the original timely filed Form 4 showed an incorrect exercise price.
- [F4]Represents the average sale price. The highest price at which shares were sold was $25.78 and the lowest price at which shares were sold was $25.71.